

Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JAN 27 Source of Registration (SR) information in REGISTRY updated
and searchable
NEWS 4 JAN 27 A new search aid, the Company Name Thesaurus, available in
CA/CAPLUS
NEWS 5 FEB 05 German (DE) application and patent publication number format
changes
NEWS 6 MAR 03 MEDLINE and LMedline reloaded
NEWS 7 MAR 03 MEDLINE file segment of TOXCENTER reloaded
NEWS 8 MAR 03 FRANCEPAT now available on STN
NEWS 9 MAR 29 Pharmaceutical Substances (PS) now available on STN
NEWS 10 MAR 29 WPIFV now available on STN
NEWS 11 MAR 29 No connect hour charges in WPIFV until May 1, 2004
NEWS 12 MAR 29 New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS 13 APR 26 PROMT: New display field available
NEWS 14 APR 26 FIPAT/IFIUDB/IFICDB: New super search and display field
available
NEWS 15 APR 26 LITAlert now available on STN
NEWS 16 APR 27 NLDB: New search and display fields available

NEWS EXPRESS MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:43:15 ON 27 APR 2004

=> file reg

Patel

<4/27/2004>

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 16:43:28 ON 27 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6
DICTIONARY FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>


Uploading c:\program files\stnexp\queries\10087715.9

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 N, CH

G2 O, S, CH2, NH

G3 O, S, NH

G4 O, S

Structure attributes must be viewed using STN Express query preparation.

=> s ll sss full

FULL SEARCH INITIATED 16:43:51 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 28122 TO ITERATE

100.0% PROCESSED 28122 ITERATIONS
SEARCH TIME: 00.00.01

180 ANSWERS

L2 180 SEA SSS FUL L1

=> file marpat

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

155.42

155.63

FILE 'MARPAT' ENTERED AT 16:44:02 ON 27 APR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 17) (20040423/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6709645 23 MAR 2004

DE 10335606 11 MAR 2004

EP 1403278 31 MAR 2004

JP 2004099560 02 APR 2004

WO 2004024934 25 MAR 2004

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=> s ll sss full

FULL SEARCH INITIATED 16:44:07 FILE 'MARPAT'

FULL SCREEN SEARCH COMPLETED - 30310 TO ITERATE

9.0% PROCESSED	2725 ITERATIONS	(2 INCOMPLETE)	10 ANSWERS
15.1% PROCESSED	4580 ITERATIONS	(3 INCOMPLETE)	21 ANSWERS
25.4% PROCESSED	7706 ITERATIONS	(8 INCOMPLETE)	41 ANSWERS
34.4% PROCESSED	10415 ITERATIONS	(15 INCOMPLETE)	61 ANSWERS
43.8% PROCESSED	13270 ITERATIONS	(17 INCOMPLETE)	83 ANSWERS
54.3% PROCESSED	16447 ITERATIONS	(22 INCOMPLETE)	104 ANSWERS
63.5% PROCESSED	19233 ITERATIONS	(35 INCOMPLETE)	138 ANSWERS
73.1% PROCESSED	22144 ITERATIONS	(40 INCOMPLETE)	157 ANSWERS

79.3% PROCESSED	24029 ITERATIONS	(47 INCOMPLETE)	178 ANSWERS
85.7% PROCESSED	25963 ITERATIONS	(52 INCOMPLETE)	204 ANSWERS
92.7% PROCESSED	28106 ITERATIONS	(62 INCOMPLETE)	229 ANSWERS
96.6% PROCESSED	29293 ITERATIONS	(67 INCOMPLETE)	246 ANSWERS
97.8% PROCESSED	29646 ITERATIONS	(69 INCOMPLETE)	250 ANSWERS
98.8% PROCESSED	29939 ITERATIONS	(72 INCOMPLETE)	257 ANSWERS
99.4% PROCESSED	30114 ITERATIONS	(73 INCOMPLETE)	260 ANSWERS
99.7% PROCESSED	30208 ITERATIONS	(74 INCOMPLETE)	262 ANSWERS
99.8% PROCESSED	30263 ITERATIONS	(74 INCOMPLETE)	262 ANSWERS
100.0% PROCESSED	30310 ITERATIONS	(74 INCOMPLETE)	264 ANSWERS

SEARCH TIME: 00.05.08

L3 264 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

112.78

268.41

FILE 'CAPLUS' ENTERED AT 16:49:32 ON 27 APR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Apr 2004 VOL 140 ISS 18

FILE LAST UPDATED: 26 Apr 2004 (20040426/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> s 12

L4 36 L2

=> s 13

L5 264 L3

CN Thiourea, N-phenyl-N'-pyrazinyl- (9CI) (CA INDEX NAME)



AB The title compds. are prepared by reacting aminopyridines, aminopyrimidines, etc., with phenylisothiocyanate (or derivs. thereof) under pressure (2 Kbar to 10 Kbar). Thus, reaction of 4-aminopyridine with phenylisothiocyanate in THF at 40° and 6 Kbar for 24 h gave the corresponding thiourea in 67% yield, vs. 28% yield in a reference process.

L4 ANSWER 5 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:695962 CAPLUS

DN 137:232680

TI Preparation of aryl and heteroaryl urea selective Chk1 inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication

IN Keegan, Kathleen S.; Kesicki, Edward A.; Gaudino, John Joseph; Cook, Adam Wade; Cowen, Scott Douglas; Burgess, Laurence Edward

PA Icos Corporation, USA

SO PCT Int. Appl., 236 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002070494	A1	20020912	WO 2002-US6452	20020301
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2003069284	A1	20030410	US 2001-273124PP	20010302
				US 2002-87715	20020301
				US 2001-273124PP	20010302
	EP 1379510	A1	20040114	EP 2002-728396	20020301
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
				US 2001-273124PP	20010302
				WO 2002-US6452 W	20020301
	NO 2003003858	A	20031010	NO 2003-3858	20030901
				US 2001-273124PP	20010302
				WO 2002-US6452 W	20020301

OS MARPAT 137:232680

IT **457096-68-3P**, 1-(2-Methoxy-5-nitrophenyl)-3-(pyrazin-2-yl)urea

457096-69-4P, 1-(5-Amino-2-methoxyphenyl)-3-(pyrazin-2-yl)urea

457096-71-8P, (S)-1-(2,2,2-Trifluoroethanoyl)pyrrolidine-2-carboxylic acid [4-methoxy-3-(3-(pyrazin-2-yl)ureido)phenyl]amide

457096-74-1P, 1-(2-Methoxy-4-nitrophenyl)-3-(pyrazin-2-yl)urea

457096-75-2P, 1-(4-Amino-2-methoxyphenyl)-3-(pyrazin-2-yl)urea

457096-78-5P, 3-Chloro-N-[3-methoxy-4-(3-(pyrazin-2-yl)ureido)phenyl]propionamide **457097-32-4P**, 4-Methoxy-3-(3-(pyrazin-2-yl)ureido)benzoic acid **457099-26-2P**,


1-(6-Azidopyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(intermediate; preparation of aryl and heteroaryl urea selective Chk1 inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)


RN 457096-68-3 CAPLUS

CN Urea, N-(2-methoxy-5-nitrophenyl)-N'-pyrazinyl- (9CI) (CA INDEX NAME)



RN 457096-69-4 CAPLUS


CN Urea, N-(5-amino-2-methoxyphenyl)-N'-pyrazinyl- (9CI) (CA INDEX NAME)



RN 457096-71-8 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[4-methoxy-3-[(pyrazinylamino)carbonyl]amino]phenyl]-1-(trifluoroacetyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 457096-74-1 CAPLUS

CN Urea, N-(2-methoxy-4-nitrophenyl)-N'-pyrazinyl- (9CI) (CA INDEX NAME)




RN 457096-75-2 CAPLUS

CN Urea, N-(4-amino-2-methoxyphenyl)-N'-pyrazinyl- (9CI) (CA INDEX NAME)




RN 457096-78-5 CAPLUS

CN Propanamide, 3-chloro-N-[3-methoxy-4-[[pyrazinylamino]carbonyl]amino]phenyl- (9CI) (CA INDEX NAME)




RN 457097-32-4 CAPLUS

CN Benzoic acid, 4-methoxy-3-[[pyrazinylamino]carbonyl]amino- (9CI) (CA INDEX NAME)



RN 457099-26-2 CAPLUS

CN Urea, N-(6-azidopyrazinyl)-N'-(2-methoxy-5-methylphenyl)- (9CI) (CA INDEX NAME)




IT **457096-84-3P**, 3-Methoxy-4-(3-(pyrazin-2-yl)ureido)benzoic acid methyl ester **457097-34-6P**, 4-Methoxy-3-(3-(pyrazin-2-yl)ureido)benzoic acid methyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of aryl and heteroaryl urea selective Chk1 inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)


RN 457096-84-3 CAPLUS

CN Benzoic acid, 3-methoxy-4-[[pyrazinylamino]carbonylamino]-, methyl ester (9CI) (CA INDEX NAME)



RN 457097-34-6 CAPLUS

CN Benzoic acid, 4-methoxy-3-[[pyrazinylamino]carbonylamino]-, methyl ester (9CI) (CA INDEX NAME)



IT **196868-94-7P**, N-(4-Chloro-2-methoxyphenyl)-N'-(2-pyrazinyl)urea
457096-65-0P, 1-[2-(1,1-Difluoromethoxy)phenyl]-3-(pyrazin-2-yl)urea **457096-67-2P**, 1-(2-Methylsulfanylphenyl)-3-(pyrazin-2-yl)urea **457096-70-7P**, N-[4-Methoxy-3-(3-(pyrazin-2-yl)ureido)phenyl]succinamic acid **457096-72-9P**, (S)-Pyrrolidine-2-carboxylic acid [4-methoxy-3-(3-(pyrazin-2-yl)ureido)phenyl]amide **457096-73-0P**, N-[4-Methoxy-3-(3-(pyrazin-2-yl)ureido)phenyl]methanesulfonamide **457096-77-4P**, C-Dimethylamino-N-[3-methoxy-4-(3-(pyrazin-2-yl)ureido)phenyl]acetamide trifluoroacetate **457096-79-6P**, N-(4-((3-(Cyclohexyl(methyl)amino)propanoyl)amino)-2-methoxyphenyl)-N'-(2-pyrazinyl)urea **457096-80-9P**, 3-(Cyclohexyl(methyl)amino)-N-[3-methoxy-4-(3-(pyrazin-2-yl)ureido)phenyl]propionamide trifluoroacetate **457096-81-0P**, 3-(Cyclopentylamino)-N-[3-methoxy-4-(3-(pyrazin-2-yl)ureido)phenyl]propionamide **457096-82-1P**, 3-Methoxy-4-(3-(pyrazin-2-yl)ureido)benzoic acid **457096-85-4P**, N-Butyl-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide **457096-87-6P**, N-Benzyl-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide **457096-89-8P**, 3-Methoxy-N-phenethyl-4-(3-(pyrazin-2-yl)ureido)benzamide **457096-90-1P**, 3-Methoxy-N-(3-phenylpropyl)-4-(3-(pyrazin-2-yl)ureido)benzamide **457096-92-3P**, N-(2-(Benzenesulfonyl)ethyl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide **457096-95-6P**, N-(4-Iodobenzyl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide **457096-97-8P** **457096-99-0P**, 3-Methoxy-4-(3-(pyrazin-2-yl)ureido)-N-(2-(pyridin-4-yl)ethyl)benzamide **457097-01-7P**, N-(1H-Benzimidazol-2-ylmethyl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide **457097-04-0P** **457097-05-1P**, 3-Methoxy-N-[3-(methylphenylamino)propyl]-4-(3-(pyrazin-2-yl)ureido)benzamide **457097-08-4P** **457097-10-8P**, N-((3R)-1-Benzylpyrrolidin-3-yl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide **457097-13-1P**, N-((3S)-1-Benzylpyrrolidin-3-yl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide **457097-16-4P**, N-(2-Dimethylaminoethyl)-3-methoxy-N-methyl-4-(3-(pyrazin-2-yl)ureido)benzamide **457097-18-6P**, 3-Methoxy-N-(3-methylaminopropyl)-4-(3-(pyrazin-2-yl)ureido)benzamide **457097-21-1P**, N-(3-Dimethylaminopropyl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide **457097-23-3P**, N-(3-Dimethylaminopropyl)-3-methoxy-N-methyl-4-(3-(pyrazin-2-yl)ureido)benzamide **457097-25-5P**, 3-Methoxy-N-(3-(morpholin-4-yl)propyl)-4-(3-(pyrazin-2-yl)ureido)benzamide **457097-27-7P**, 3-Methoxy-N-[3-(4-methylpiperazin-1-yl)propyl]-4-(3-(pyrazin-2-yl)ureido)benzamide **457097-29-9P**, [2-[3-Methoxy-4-(3-(pyrazin-2-yl)ureido)benzoylamino]ethyl]trimethylammonium chloride **457097-35-7P**, N-Butyl-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide **457097-36-8P**, N-Benzyl-4-methoxy-3-(3-


(pyrazin-2-yl)ureido)benzamide **457097-37-9P**,
 4-Methoxy-N-phenethyl-3-(3-(pyrazin-2-yl)ureido)benzamide
457097-38-0P, 4-Methoxy-N-(3-phenylpropyl)-3-(3-(pyrazin-2-yl)ureido)benzamide **457097-39-1P**, N-(2-(Benzenesulfonyl)ethyl)-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide **457097-40-4P**,
 4-Methoxy-3-(3-(pyrazin-2-yl)ureido)-N-(2-(pyridin-2-yl)ethyl)benzamide **457097-41-5P**, 4-Methoxy-3-(3-(pyrazin-2-yl)ureido)-N-(2-(pyridin-4-yl)ethyl)benzamide **457097-42-6P**, N-(1H-Benzimidazol-2-ylmethyl)-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide **457097-43-7P**,
 N-[2-(1H-Indol-3-yl)ethyl]-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide **457097-44-8P**, 4-Methoxy-N-[3-(methylphenylamino)propyl]-3-(3-(pyrazin-2-yl)ureido)benzamide **457097-45-9P** **457097-46-0P**,
 N-(2-Dimethylaminoethyl)-4-methoxy-N-methyl-3-(3-(pyrazin-2-yl)ureido)benzamide **457097-47-1P**, 4-Methoxy-N-(3-methylaminopropyl)-3-(3-(pyrazin-2-yl)ureido)benzamide **457097-48-2P**,
 N-(3-Dimethylaminopropyl)-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide **457097-49-3P**, N-(3-Dimethylaminopropyl)-4-methoxy-N-methyl-3-(3-(pyrazin-2-yl)ureido)benzamide **457097-50-6P**,
 4-Methoxy-N-[3-(4-methylpiperazin-1-yl)propyl]-3-(3-(pyrazin-2-yl)ureido)benzamide **457097-51-7P**, [2-[4-Methoxy-3-(3-(pyrazin-2-yl)ureido)benzoylamino]ethyl]trimethylammonium chloride **457097-52-8P**,
 4-Methoxy-N-(3-(morpholin-4-yl)propyl)-3-(3-(pyrazin-2-yl)ureido)benzamide **457098-38-3P**, 1-[2-(3-Dimethylaminopropoxy)-5-methylphenyl]-3-(pyrazin-2-yl)urea **457098-41-8P**,
 1-[2-(2-Dimethylaminoethoxy)-5-methylphenyl]-3-(pyrazin-2-yl)urea **457098-42-9P**, 1-[5-Methyl-2-(pyridin-3-ylmethoxy)phenyl]-3-(pyrazin-2-yl)urea **457098-43-0P**,
 1-[5-Methyl-2-[3-(2-oxopyrrolidin-1-yl)propoxy]phenyl]-3-(pyrazin-2-yl)urea **457098-44-1P**, 1-[5-Methyl-2-(2-(morpholin-4-yl)ethoxy)phenyl]-3-(pyrazin-2-yl)urea **457099-27-3P**,
 1-(6-Aminopyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea **457099-28-4P**, 1-(6-Chloropyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea **457099-35-3P**,
 1-(2-Methoxy-5-methylphenyl)-3-(6-methoxypyrazin-2-yl)urea **457099-37-5P**, 1-(6-Benzyloxypyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea **457099-50-2P**,
 1-(3,6-Dimethylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea **457099-93-3P**, N-(2-Methoxy-3-((2-(4-morpholinyl)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea **457099-94-4P**,
 N-(2-Methoxy-3-((2-(1-methylpyrrolidin-2-yl)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea **457099-95-5P**, N-(4-((2-Chloroethyl)carbamoyl)-2-methoxyphenyl)-N'-(2-pyrazinyl)urea **457099-96-6P**,
 N-(2-Methoxy-4-((2-(4-morpholinyl)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea **457099-97-7P**, N-(2-Methoxy-4-((2-(1-methylpyrrolidin-2-yl)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea **457099-98-8P**,
 N-(2-Methoxy-4-((2-((methylsulfonyl)amino)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea **457099-99-9P**, N-(3-(Ethyl(methyl)carbamoyl)-2-methoxyphenyl)-N'-(2-pyrazinyl)urea **457100-02-6P**,
 N-(2-Methoxy-5-methylphenyl)-N'-(6-phenyl-2-pyrazinyl)urea **457100-03-7P**, N-(2-Methoxy-5-methylphenyl)-N'-(2-pyrazinyl)urea **457100-04-8P**,
 N-(4-((3-(Dimethylamino)propanoyl)amino)-2-methoxyphenyl)-N'-(2-pyrazinyl)urea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aryl and heteroaryl urea selective Chk1 inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)


RN 196868-94-7 CAPLUS

CN Urea, N-(4-chloro-2-methoxyphenyl)-N'-pyrazinyl- (9CI) (CA INDEX NAME)




RN 457096-65-0 CAPLUS

CN Urea, N-[2-(difluoromethoxy)phenyl]-N'-pyrazinyl- (9CI) (CA INDEX NAME)




RN 457096-67-2 CAPLUS

CN Urea, N-[2-(methylthio)phenyl]-N'-pyrazinyl- (9CI) (CA INDEX NAME)



RN 457096-70-7 CAPLUS


CN Butanoic acid, 4-[[4-methoxy-3-[[(pyrazinylamino) carbonyl] amino] phenyl] amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 457096-72-9 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[4-methoxy-3-[[(pyrazinylamino) carbonyl] amino] phenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457096-73-0 CAPLUS

CN Methanesulfonamide, N-[4-methoxy-3-[[pyrazinylamino]carbonyl]amino]phenyl
]- (9CI) (CA INDEX NAME)




RN 457096-77-4 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-[3-methoxy-4-[[pyrazinylamino]carbonyl]ami
no]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 457096-76-3


CMF C16 H20 N6 O3




CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 457096-79-6 CAPLUS

CN Propanamide, 3-(cyclohexylmethylamino)-N-[3-methoxy-4-
[[pyrazinylamino)carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)


RN 457096-80-9 CAPLUS

CN Propanamide, 3-(cyclohexylmethylamino)-N-[3-methoxy-4-
[[pyrazinylamino)carbonyl]amino]phenyl]-, trifluoroacetate (9CI) (CA
INDEX NAME)

CM 1

CRN 457096-79-6


CMF C22 H30 N6 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 457096-81-0 CAPLUS


CN Propanamide, 3-(cyclopentylamino)-N-[3-methoxy-4-

[[(pyrazinylamino) carbonyl] amino] phenyl] - (9CI) (CA INDEX NAME)




RN 457096-82-1 CAPLUS

CN Benzoic acid, 3-methoxy-4-[[(pyrazinylamino) carbonyl] amino] - (9CI) (CA INDEX NAME)




RN 457096-85-4 CAPLUS

CN Benzamide, N-butyl-3-methoxy-4-[[(pyrazinylamino) carbonyl] amino] - (9CI) (CA INDEX NAME)




RN 457096-87-6 CAPLUS

CN Benzamide, 3-methoxy-N-(phenylmethyl)-4-[[(pyrazinylamino) carbonyl] amino] - (9CI) (CA INDEX NAME)




RN 457096-89-8 CAPLUS


CN Benzamide, 3-methoxy-N-(2-phenylethyl)-4-[[(pyrazinylamino) carbonyl] amino] - (9CI) (CA INDEX NAME)




RN 457096-90-1 CAPLUS

CN Benzamide, 3-methoxy-N-(3-phenylpropyl)-4-[[(pyrazinylamino) carbonyl] amino]
]- (9CI) (CA INDEX NAME)

RN 457096-92-3 CAPLUS


CN Benzamide, 3-methoxy-N-[2-(phenylsulfonyl)ethyl]-4-
[[(pyrazinylamino) carbonyl] amino]- (9CI) (CA INDEX NAME)

RN 457096-95-6 CAPLUS

CN Benzamide, N-[(4-iodophenyl)methyl]-3-methoxy-4-
[[(pyrazinylamino) carbonyl] amino]- (9CI) (CA INDEX NAME)


RN 457096-97-8 CAPLUS

CN Benzamide, 3-methoxy-4-[[(pyrazinylamino) carbonyl] amino]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 457096-99-0 CAPLUS

CN Benzamide, 3-methoxy-4-[[(pyrazinylamino) carbonyl] amino]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 457097-01-7 CAPLUS

CN Benzamide, N-(1H-benzimidazol-2-ylmethyl)-3-methoxy-4-[[(pyrazinylamino) carbonyl] amino]- (9CI) (CA INDEX NAME)




RN 457097-04-0 CAPLUS

CN Benzamide, N-[2-(1H-indol-3-yl)ethyl]-3-methoxy-4-[[(pyrazinylamino) carbonyl] amino]- (9CI) (CA INDEX NAME)



RN 457097-05-1 CAPLUS


CN Benzamide, 3-methoxy-N-[3-(methylphenylamino)propyl]-4-[[(pyrazinylamino) carbonyl] amino]- (9CI) (CA INDEX NAME)




RN 457097-08-4 CAPLUS

CN Benzamide, 3-methoxy-N-[1-(phenylmethyl)-3-pyrrolidinyl]-4-
[[pyrazinylamino]carbonylamino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 457097-10-8 CAPLUS

CN Benzamide, 3-methoxy-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]-4-
[[pyrazinylamino]carbonylamino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 457097-13-1 CAPLUS


CN Benzamide, 3-methoxy-N-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]-4-
[[(pyrazinylamino) carbonyl] amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 457097-16-4 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-3-methoxy-N-methyl-4-
[[(pyrazinylamino) carbonyl] amino]- (9CI) (CA INDEX NAME)




RN 457097-18-6 CAPLUS


CN Benzamide, 3-methoxy-N-[3-(methylamino)propyl]-4-
[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-21-1 CAPLUS
CN Benzamide, N-[3-(dimethylamino)propyl]-3-methoxy-4-
[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-23-3 CAPLUS
CN Benzamide, N-[3-(dimethylamino)propyl]-3-methoxy-N-methyl-4-
[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-25-5 CAPLUS
CN Benzamide, 3-methoxy-N-[3-(4-morpholinyl)propyl]-4-
[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-27-7 CAPLUS


CN Benzamide, 3-methoxy-N-[3-(4-methyl-1-piperazinyl)propyl]-4-
[[(pyrazinylamino) carbonyl] amino] - (9CI) (CA INDEX NAME)

RN 457097-29-9 CAPLUS

CN Ethanaminium, 2-[[3-methoxy-4-[[(pyrazinylamino) carbonyl] amino] benzoyl] amino]-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)


● Cl⁻

RN 457097-35-7 CAPLUS

CN Benzamide, N-butyl-4-methoxy-3-[[(pyrazinylamino) carbonyl] amino] - (9CI)
(CA INDEX NAME)


RN 457097-36-8 CAPLUS

CN Benzamide, 4-methoxy-N-(phenylmethyl)-3-[[(pyrazinylamino) carbonyl] amino] -
(9CI) (CA INDEX NAME)




RN 457097-37-9 CAPLUS

CN Benzamide, 4-methoxy-N-(2-phenylethyl)-3-[[pyrazinylamino]carbonyl]-
(9CI) (CA INDEX NAME)




RN 457097-38-0 CAPLUS

CN Benzamide, 4-methoxy-N-(3-phenylpropyl)-3-[[pyrazinylamino]carbonyl]-
]- (9CI) (CA INDEX NAME)




RN 457097-39-1 CAPLUS

CN Benzamide, 4-methoxy-N-[2-(phenylsulfonyl)ethyl]-3-
[[pyrazinylamino]carbonyl]- (9CI) (CA INDEX NAME)




RN 457097-40-4 CAPLUS

CN Benzamide, 4-methoxy-3-[[(pyrazinylamino) carbonyl] amino]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 457097-41-5 CAPLUS

CN Benzamide, 4-methoxy-3-[[(pyrazinylamino) carbonyl] amino]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 457097-42-6 CAPLUS

CN Benzamide, N-(1H-benzimidazol-2-ylmethyl)-4-methoxy-3-[[(pyrazinylamino) carbonyl] amino]- (9CI) (CA INDEX NAME)




RN 457097-43-7 CAPLUS


CN Benzamide, N-[2-(1H-indol-3-yl)ethyl]-4-methoxy-3-[[(pyrazinylamino) carbonyl] amino]- (9CI) (CA INDEX NAME)



RN 457097-44-8 CAPLUS


CN Benzamide, 4-methoxy-N-[3-(methylphenylamino)propyl]-3-
[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)

RN 457097-45-9 CAPLUS

CN Benzamide, 4-methoxy-N-[1-(phenylmethyl)-3-pyrrolidinyl]-3-
[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)


RN 457097-46-0 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-4-methoxy-N-methyl-3-
[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-47-1 CAPLUS

CN Benzamide, 4-methoxy-N-[3-(methylamino)propyl]-3-
[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-48-2 CAPLUS

CN Benzamide, N-[3-(dimethylamino)propyl]-4-methoxy-3-
[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-49-3 CAPLUS


CN Benzamide, N-[3-(dimethylamino)propyl]-4-methoxy-N-methyl-3-
[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-50-6 CAPLUS

CN Benzamide, 4-methoxy-N-[3-(4-methyl-1-piperazinyl)propyl]-3-
[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)


RN 457097-51-7 CAPLUS

CN Ethanaminium, 2-[[4-methoxy-3-[[pyrazinylamino]carbonyl]amino]benzoyl]ami-
no]-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)● Cl⁻


RN 457097-52-8 CAPLUS

CN Benzamide, 4-methoxy-N-[3-(4-morpholinyl)propyl]-3-
[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)


RN 457098-38-3 CAPLUS

CN Urea, N-[2-[3-(dimethylamino)propoxy]-5-methylphenyl]-N'-pyrazinyl- (9CI)
(CA INDEX NAME)

RN 457098-41-8 CAPLUS


CN Urea, N-[2-[2-(dimethylamino)ethoxy]-5-methylphenyl]-N'-pyrazinyl- (9CI)
(CA INDEX NAME)

RN 457098-42-9 CAPLUS

CN Urea, N-[5-methyl-2-(3-pyridinylmethoxy)phenyl]-N'-pyrazinyl- (9CI) (CA
INDEX NAME)


RN 457098-43-0 CAPLUS

CN Urea, N-[5-methyl-2-[3-(2-oxo-1-pyrrolidinyl)propoxy]phenyl]-N'-pyrazinyl-
(9CI) (CA INDEX NAME)




RN 457098-44-1 CAPLUS

CN Urea, N-[5-methyl-2-[2-(4-morpholinyl)ethoxy]phenyl]-N'-pyrazinyl- (9CI)
(CA INDEX NAME)




RN 457099-27-3 CAPLUS

CN Urea, N-(6-aminopyrazinyl)-N'-(2-methoxy-5-methylphenyl)- (9CI) (CA INDEX NAME)




RN 457099-28-4 CAPLUS

CN Urea, N-(6-chloropyrazinyl)-N'-(2-methoxy-5-methylphenyl)- (9CI) (CA INDEX NAME)




RN 457099-35-3 CAPLUS

CN Urea, N-(2-methoxy-5-methylphenyl)-N'-(6-methoxypyrazinyl)- (9CI) (CA INDEX NAME)




RN 457099-37-5 CAPLUS

CN Urea, N-(2-methoxy-5-methylphenyl)-N'-[6-(phenylmethoxy)pyrazinyl]- (9CI) (CA INDEX NAME)




RN 457099-50-2 CAPLUS

CN Urea, N-(3,6-dimethylpyrazinyl)-N'-(2-methoxy-5-methylphenyl)- (9CI) (CA INDEX NAME)




RN 457099-93-3 CAPLUS

CN Benzamide, 2-methoxy-N-[2-(4-morpholinyl)ethyl]-3-
[[pyrazinylamino]carbonylamino]- (9CI) (CA INDEX NAME)




RN 457099-94-4 CAPLUS

CN Benzamide, 2-methoxy-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-3-
[[pyrazinylamino]carbonylamino]- (9CI) (CA INDEX NAME)




RN 457099-95-5 CAPLUS

CN Benzamide, N-(2-chloroethyl)-3-methoxy-4-[[pyrazinylamino]carbonylamino]-
(9CI) (CA INDEX NAME)




RN 457099-96-6 CAPLUS

CN Benzamide, 3-methoxy-N-[2-(4-morpholinyl)ethyl]-4-
[[pyrazinylamino]carbonylamino]- (9CI) (CA INDEX NAME)




RN 457099-97-7 CAPLUS


CN Benzamide, 3-methoxy-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-
[[pyrazinylamino]carbonylamino]- (9CI) (CA INDEX NAME)




RN 457099-98-8 CAPLUS

CN Benzamide, 3-methoxy-N-[2-[(methylsulfonyl)amino]ethyl]-4-
[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)

RN 457099-99-9 CAPLUS


CN Benzamide, N-ethyl-2-methoxy-N-methyl-3-[[pyrazinylamino]carbonyl]amino]-
(9CI) (CA INDEX NAME)

RN 457100-02-6 CAPLUS


CN Urea, N-(2-methoxy-5-methylphenyl)-N'-(6-phenylpyrazinyl)- (9CI) (CA
INDEX NAME)

RN 457100-03-7 CAPLUS

CN Urea, N-(2-methoxy-5-methylphenyl)-N'-pyrazinyl- (9CI) (CA INDEX NAME)



RN 457100-04-8 CAPLUS

CN Propanamide, 3-(dimethylamino)-N-[3-methoxy-4-
[[pyrazinylamino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)

AB Aryl- and heteroaryl substituted urea compds. (W'NHC(:Y')N(R13)Z'; 1) useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. In 1, W' is a six-membered aromatic ring containing at least 2 nitrogen atoms (e.g. pyrazinyl, pyrimidinyl, pyridazinyl, 1,2,4-triazinyl, quinoxalinyl) and optionally substituted as defined in the claims, Z' is a five- or six membered aromatic or heteroarom. ring as defined in the claims, Y' is O or S. The first claim contains a much more general formula WX1C(:Y)X2Z (e.g. X1 = null, O, S, CH2, NR1; X2 = O, S, NR1) but emphasis is on 1. Methods of making the compds., and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are described. Although the methods of preparation are not claimed, about 200 example prepns. are included. N-(2-methoxy-5-methylphenyl)-N'-(2-pyrazinyl)urea and N-(4-chloro-2-methoxyphenyl)-N'-(2-pyrazinyl)urea enhanced the killing of various human cells by 5-fluorouracil from 2- to 10-fold; in HeLa cells, these same compds. enhanced killing by irradiation 2-3 fold.

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:591913 CAPLUS

DN 137:150215

TI Cdk4 and/or Cdk6 inhibitors with biaryl ureas and their salts as antitumor agents

IN Hatayama, Satoshi; Hayashi, Kyoko; Honma, Mitsuki; Takahashi, Ikuko

PA Banyu Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 194 pp.


CODEN: JKXXAF

oxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, quinoxalinyl, quinolyl, etc.; W2 = single bond, O, S, SO, SO₂, N-(un)substituted NH, SO₂NH, NHSO₂NH, NHSO₂, CONH, NHCO, NHCONH, NHCO₂, etc.; Y3, Y4 = single bond, linear or branched lower alkylene; R2 and R3 each represents hydrogen, lower alkyl or alkoxy, or Y3-W2-Y4-R5 (Y3, W2, Y4, R5 = same as above), or one of R2 and R3 together with R1 and X forms cyclohexane, cyclopentane, piperidine, 3,4,5,6-tetrahydro-1,3-oxazine, tetrahydrothiopyran, pyrrolidine, tetrahydrothiofuran, oxazolidine ring, etc.; R4 and R5 represent H, halo, OH, amino, or Y3-W2-Y4-R5 (Y3, W2, Y4, R5 = same as above)] or salts thereof are prepared. The compds. (e.g. II) have a remarkable proliferation-inhibitory effect on tumor cells. A Cdk4 and/or Cdk6 inhibitor for use in the therapy of malignant tumor can hence be provided. II showed IC₅₀ of 0.061 and 0.019 μ M against cyclin-D1-Cdk4 and cyclin-D2-Cdk4, resp., vs. 0.36 and 0.056 μ M, resp., for (\pm)-flavopiridol, and inhibited the proliferation of HCT116 and MKN-1 cells with IC₅₀ of 0.013 and 0.10 μ M, resp., vs. 0.15 and 0.87 μ M, resp., for (\pm)-flavopiridol. Pharmaceutical formulations containing I were prepared


RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:508648 CAPLUS
DN 133:281683
TI Quinolones as gonadotropin releasing hormone (GnRH) antagonists:
simultaneous optimization of the C(3)-aryl and C(6)-substituents
AU Young, J. R.; Huang, S. X.; Chen, I.; Walsh, T. F.; DeVita, R. J.;
Wyvratt, M. J.; Goulet, M. T.; Ren, N.; Lo, J.; Yang, Y. T.; Yudkovitz, J.
B.; Cheng, K.; Smith, R. G.
CS PO Box 2000, Departments of Medicinal Chemistry, Merck Research
Laboratories, Rahway, NJ, 07065, USA
SO Bioorganic & Medicinal Chemistry Letters (2000), 10(15), 1723-1727
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
IT **199859-57-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological
study); PREP (Preparation)
(preparation of arylquinolones as gonadotropin releasing hormone
antagonists)
RN 199859-57-9 CAPLUS
CN Urea, N-[7-chloro-3-(3,5-dimethylphenyl)-1,2-dihydro-2-oxo-4-[2-(2S)-2-
piperidinylethoxy]-6-quinolinyl]-N'-pyrazinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB A series of 3-arylquinolones was prepared and evaluated for their ability to act as gonadotropin releasing hormone (GnRH) antagonists. A variety of substitution patterns of the 3-aryl substituent are described. The 3,4,5-trimethylphenyl substituent (I) was found to be optimal.

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:433763 CAPLUS
DN 134:56645
TI Reactivity studies of 5,6-dimethyl- and 3,5,6-trimethyl-1,2,4-triazine-N4-oxide against different electrophiles
AU Cerecetto, H.; Gonzalez, M.; Saenz, P.; Seoane, G.
CS Catedra de Quimica Organica, Facultad de Quimica, Universidad de la Republica General Flores, Montevideo, 2124, Urug.
SO Molecules [Electronic Publication] (2000), 5(3), 501-502
CODEN: MOLEFW; ISSN: 1420-3049
URL: <http://www.mdpi.org/molecules/papers/50300252.pdf>

DE 19749979 A1 19990506
 DE 19749979 C2 20000113
 AU 9917532 A1 19990531

DE 1997-19749979A 19971105
 US 1997-65885P P 19971117
 DE 1997-19749979 19971105
 AU 1999-17532 19981104
 DE 1997-19749979A 19971105
 US 1997-65885P P 19971117
 WO 1998-EP6934 W 19981104

PATENT FAMILY INFORMATION:

FAN 1999:307416

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19749979	A1	19990506	DE 1997-19749979	19971105
	DE 19749979	C2	20000113		
	ZA 9810080	A	19990405	ZA 1998-10080	19981104
	WO 9924403	A1	19990520	DE 1997-19749979A	19971105
				WO 1998-EP6934	19981104
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
				DE 1997-19749979A	19971105
				US 1997-65885P P	19971117
	AU 9917532	A1	19990531	AU 1999-17532	19981104
				DE 1997-19749979A	19971105
				US 1997-65885P P	19971117
				WO 1998-EP6934 W	19981104


OS MARPAT 130:338023

IT **224580-21-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of methylenebis(ureidophenyl) and analog interleukin 4 inhibitors)

RN 224580-21-6 CAPLUS

CN Urea, N,N'-(methylenedi-4,1-phenylene)bis[N'-pyrazinyl- (9CI) (CA INDEX NAME)




AB Z(Z1NHCONHR)2 [I; R = (cyclo)alkyl, (un)substituted (hetero)arylalkyl; Z = alkylene, O, CO, NH, etc.; Z1 = (un)substituted phenylene] were prepared Thus, CH2[C6H4(NCO)-4]2 was amidated by 3-picolylamine to give CH2[C6H4(NHCONHR)-4]2 (R = 3-pyridylmethyl). Data for biol. activity of I were given.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Preparation of indolylurea derivatives as antagonists
 IN Forbes, Ian Thomson; Martin, Roger Thomas; Jones, Graham Elgin
 PA SmithKline Beecham PLC, UK
 SO PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9318028	A1	19930916	WO 1993-GB449	19930304
	W: AU, CA, JP, KR, NZ, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				GB 1992-5415	19920312
				GB 1992-5416	19920312
				GB 1992-5422	19920312
				GB 1992-5442	19920312
	AU 9336411	A1	19931005	AU 1993-36411	19930304
				GB 1992-5415	19920312
				GB 1992-5416	19920312
				GB 1992-5422	19920312
				GB 1992-5442	19920312
				WO 1993-GB449	19930304
				EP 1993-905507	19930304
	EP 630373	A1	19941228		
	R: BE, CH, DE, FR, GB, IT, LI, NL				
				GB 1992-5415	19920312
				GB 1992-5416	19920312
				GB 1992-5422	19920312
				GB 1992-5442	19920312
				WO 1993-GB449	19930304
	JP 07504429	T2	19950518	JP 1993-515449	19930304
				GB 1992-5415	19920312
				GB 1992-5416	19920312
				GB 1992-5422	19920312
				GB 1992-5442	19920312
				WO 1993-GB449	19930304
	ZA 9301713	A	19940922	ZA 1993-1713	19930310
				GB 1992-5415	19920312
	US 5508288	A	19960416	US 1994-295694	19940830
				GB 1992-5415	19920312
				GB 1992-5416	19920312
				GB 1992-5422	19920312
				GB 1992-5442	19920312
				WO 1993-GB449	19930304
OS	MARPAT 120:77171				
IT	152239-42-4P				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(preparation of, as 5-HT1c antagonists)				
RN	152239-42-4 CAPLUS				
CN	Urea, N-(1-methyl-1H-indol-5-yl)-N'-pyrazinyl- (9CI) (CA INDEX NAME)				



GI



AB Title compds. I (P = quinolinyl, isoquinolyl, 5,6-membered heterocyclyl; R1 = H, C1-6 alkyl; R2, R3, R10, R11 = C2-6 alkylene; R4 = H, C1-6 alkyl, halo, R8R9N, R12O, R12O2C wherein R8, R9, R12 = H, C1-6 alkyl; R5, R6 = H, C1-6 alkyl; R7 = H, C1-6 alkyl, C1-6 alkoxy, halo; etc.) or a salt thereof, are prepared to NaH was added 5-amino-3-methylbisthiazole-HCl followed by N-(1-methyl-5-indolyl)carbamate (preparation given) to give the title compound II. The affinity of II for 5-HT1C binding site by assessing its ability to displace [3H]-mesulergine from 5-HT1C binding sites was shown by pA2 as 7.9.

L4 ANSWER 30 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1990:497303 CAPLUS

DN 113:97303

TI A new approach for the synthesis of pteridines: the synthesis of 3-substituted-2-thioxo-1,2-dihydro-4(3H)-pteridinones

AU Urleb, Uros; Neidlein, Richard; Kramer, Walter

CS Pharm.-Chem. Inst., Univ. Heidelberg, Heidelberg, D-6900, Germany

SO Journal of Heterocyclic Chemistry (1990), 27(2), 433-7

CODEN: JHTCAD; ISSN: 0022-152X

DT Journal

LA English


OS CASREACT 113:97303

IT **128890-22-2P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 128890-22-2 CAPLUS

CN Pyrazinecarboxylic acid, 3-[[(phenylamino)thioxomethyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



AB RNR4C(:NR5)X4X5R8 [I; R = azine groups Q1 or Q2; R1 = (un)substituted Ph, -heterocyclyl; R2, R4 = H, alkyl; R3 = H, halo, alkyl, alkoxy; R5 = H, (hydroxy)alkyl, OH, Ph; R8 = (cyclo)alkyl, Ph, heterocyclyl, etc.; X1-X3 = CH; 1 of X1-X3 may = N; X4 = CH2, NR6; R6 = H, alkyl; X5 = bond, CH2, NR7; R7 = H, alkyl] were prepared Thus, 2-amino-6-benzylpyridine (preparation given) was N-acylated with PhNCS and the product treated with NH3 and HgO to give title compound II. I had IC50 of <55mM against K+-stimulated ATPase activity in lyophilized gastric vesicles in vitro.

L6 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1995:733459 CAPLUS

DN **123:143653**

TI Biaryl ureas and related compounds for use as cardiovascular agents.

IN Atwal, Karnail; Ferrara, Francis N.; Ding, Charles Z.

PA USA

SO Can. Pat. Appl., 39 pp.

CODEN: CPXXEB

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2132771	AA	19950408	CA 1994-2132771	19940923
	US 5547966	A	19960820	US 1993-134195	19931007
	EP 656350	A1	19950607	US 1993-134195	19931007
				EP 1994-306813	19940916
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			US 1993-134195	19931007
	AU 9474463	A1	19950427	AU 1994-74463	19941006
	AU 690133	B2	19980423		
				US 1993-134195	19931007
	JP 07188151	A2	19950725	JP 1994-243895	19941007
				US 1993-134195	19931007

OS MARPAT 123:143653


IT **166263-12-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of biaryl ureas and analogs as cardiovascular agents)

RN 166263-12-3 CAPLUS

CN Urea, N-[5-cyano-2-(1,1-dimethylethyl)phenyl]-N'-pyrazinyl- (9CI) (CA INDEX NAME)



GI



AB Title compds. I [X = single bond, O, CO, S, NH, or alkylimino; Y = O, S, or NCN; R1 = alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R2 = H, alkyl, haloalkyl, alkenyl, alkynyl, cyano, NO₂, CHO, CO₂H, halo, (un)substituted amino, etc.; R3 = H, alkyl, OH, alkoxy, (un)substituted amino, cyano, NO₂; R4 = aryl, aralkyl, heterocyclo, heterocycloalkyl; R5, R5' = H, alkyl, (un)substituted alkylamino, haloalkyl; or R4R5 form ring with 5 to 7 members and optional O, S, or (un)substituted NH] and salts are claimed, along with 18 specific compds. which were also prepared These compds. have potassium channel activating activity and are useful, e.g., as cardiovascular agents (no data). For example, tert-butylbenzene underwent 2,4-dinitration (70%), reduction of the 4-nitro group to amino (86%), diazotization and cyanation of the group to give a benzonitrile (42%), and reduction of the remaining nitro group with SnCl₂ (100%) to give 3-amino-4-(tert-butyl)benzonitrile. Reaction of this with benzyl isocyanate gave title compound II in 70% yield.

L6 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1994:77171 CAPLUS

DN **120:77171**

TI Preparation of indolylurea derivatives as antagonists

IN Forbes, Ian Thomson; Martin, Roger Thomas; Jones, Graham Elgin

PA SmithKline Beecham PLC, UK

SO PCT Int. Appl., 36 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9318028	A1	19930916	WO 1993-GB449	19930304
	W: AU, CA, JP, KR, NZ, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				GB 1992-5415	19920312
				GB 1992-5416	19920312
				GB 1992-5422	19920312
				GB 1992-5442	19920312
	AU 9336411	A1	19931005	AU 1993-36411	19930304
				GB 1992-5415	19920312
				GB 1992-5416	19920312
				GB 1992-5422	19920312
				GB 1992-5442	19920312
				WO 1993-GB449	19930304
	EP 630373	A1	19941228	EP 1993-905507	19930304
	R: BE, CH, DE, FR, GB, IT, LI, NL				
				GB 1992-5415	19920312
				GB 1992-5416	19920312
				GB 1992-5422	19920312
				GB 1992-5442	19920312
				WO 1993-GB449	19930304
	JP 07504429	T2	19950518	JP 1993-515449	19930304
				GB 1992-5415	19920312
				GB 1992-5416	19920312
				GB 1992-5422	19920312
				GB 1992-5442	19920312
				WO 1993-GB449	19930304
	ZA 9301713	A	19940922	ZA 1993-1713	19930310
				GB 1992-5415	19920312
	US 5508288	A	19960416	US 1994-295694	19940830
				GB 1992-5415	19920312
				GB 1992-5416	19920312
				GB 1992-5422	19920312
				GB 1992-5442	19920312
				WO 1993-GB449	19930304
OS	MARPAT 120:77171				
IT	152239-42-4P				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(preparation of, as 5-HT1c antagonists)				
RN	152239-42-4 CAPLUS				
CN	Urea, N-(1-methyl-1H-indol-5-yl)-N'-pyrazinyl- (9CI)			(CA INDEX NAME)	



GI

Patel

<4/27/2004>



AB Title compds. I (P = quinolinyl, isoquinolyl, 5,6-membered heterocyclyl; R1 = H, C1-6 alkyl; R2, R3, R10, R11 = C2-6 alkylene; R4 = H, C1-6 alkyl, halo, R8R9N, R12O, R12O2C wherein R8, R9, R12 = H, C1-6 alkyl; R5, R6 = H, C1-6 alkyl; R7 = H, C1-6 alkyl, C1-6 alkoxy, halo; etc.) or a salt thereof, are prepared to NaH was added 5-amino-3-methylbisthiazole-HCl followed by N-(1-methyl-5-indolyl)carbamate (preparation given) to give the title compound II. The affinity of II for 5-HT1C binding site by assessing its ability to displace [3H]-mesulergine from 5-HT1C binding sites was shown by pA2 as 7.9.

=> d his

(FILE 'HOME' ENTERED AT 16:43:15 ON 27 APR 2004)

FILE 'REGISTRY' ENTERED AT 16:43:28 ON 27 APR 2004

L1 STRUCTURE UPLOADED

L2 180 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 16:44:02 ON 27 APR 2004

L3 264 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 16:49:32 ON 27 APR 2004

L4 36 S L2

L5 264 S L3

L6 10 S L4 AND L5

=> d 15 fbuib hitstr abs total

'FBUIB' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB

ALL ----- BIB, AB, IND, RE

APPS ----- AI, PRAI

BIB ----- AN, plus Bibliographic Data and PI table (default)

CAN ----- List of CA abstract numbers without answer numbers

CBIB ----- AN, plus Compressed Bibliographic Data

DALL ----- ALL, delimited (end of each field identified)

DMAX ----- MAX, delimited for post-processing